Huadong Medicine Co Ltd
SZSE:000963
Gross Margin
Huadong Medicine Co Ltd
Gross Margin is the amount of money a company retains after incurring the direct costs associated with producing the goods it sells and the services it provides. The higher the gross margin, the more capital a company retains, which it can then use to pay other costs or satisfy debt obligations.
Gross Margin Across Competitors
| Country | Company | Market Cap |
Gross Margin |
||
|---|---|---|---|---|---|
| CN |
|
Huadong Medicine Co Ltd
SZSE:000963
|
64.6B CNY |
32%
|
|
| US |
|
Mckesson Corp
NYSE:MCK
|
85.6B USD |
4%
|
|
| US |
|
Cencora Inc
NYSE:COR
|
54.1B USD |
3%
|
|
| US |
A
|
Amerisourcebergen Corp
LSE:0HF3
|
53.2B USD |
3%
|
|
| US |
|
Cardinal Health Inc
NYSE:CAH
|
31.2B USD |
3%
|
|
| AU |
|
Sigma Healthcare Ltd
ASX:SIG
|
34.6B AUD |
9%
|
|
| KR |
|
Celltrion Healthcare Co Ltd
KOSDAQ:091990
|
12.2T KRW |
30%
|
|
| AU |
E
|
EBOS Group Ltd
OTC:EBOSY
|
8.2B USD |
13%
|
|
| US |
|
Henry Schein Inc
NASDAQ:HSIC
|
7.9B USD |
32%
|
|
| CN |
|
Shanghai Pharmaceuticals Holding Co Ltd
SSE:601607
|
53.3B CNY |
11%
|
|
| CN |
|
Sinopharm Group Co Ltd
HKEX:1099
|
55.6B HKD |
8%
|
Huadong Medicine Co Ltd
Glance View
Huadong Medicine Co., Ltd., a key player in China's pharmaceutical landscape, was established with a vision to integrate research, development, manufacturing, and distribution of pharmaceutical products. The company operates a diverse portfolio comprising prescription medicines, over-the-counter products, and active pharmaceutical ingredients. Central to its strategy is a robust focus on innovation and quality, enabling it to effectively cater to various therapeutic areas, including oncology, endocrinology, and nephrology. Huadong Medicine benefits from its substantial investment in research and development, with state-of-the-art facilities that drive advancements and partnerships with global biotech firms, thereby underscoring its commitment to bringing cutting-edge medical solutions to the market. At the heart of Huadong Medicine’s business model is a well-coordinated infrastructure that seamlessly blends manufacturing excellence with a sophisticated distribution network. This dynamic framework ensures the efficient delivery of products across China and into international markets, supporting a significant revenue stream. Additionally, the company's active pharmaceutical ingredients (API) division forms a crucial component of its operations, supplying high-quality raw materials to both domestic and international pharmaceutical companies. By maintaining a strategic balance between product innovation and operational efficiency, Huadong Medicine not only sustains its competitive advantage but also continually scales its presence in the global pharmaceutical industry, carving out a prominent niche in an increasingly competitive arena.
See Also
Gross Margin is the amount of money a company retains after incurring the direct costs associated with producing the goods it sells and the services it provides. The higher the gross margin, the more capital a company retains, which it can then use to pay other costs or satisfy debt obligations.
Based on Huadong Medicine Co Ltd's most recent financial statements, the company has Gross Margin of 32.3%.
You don't have any saved screeners yet